ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary ...( - New Data from Open Label Study and...),Health

- New Data from Open Label Study and New Data Suggesting Need for Improved

HAE Screening Presented at ACAAI 2008 Annual Meeting -

EXTON, Pa., Nov. 12 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of data from its ongoing, open-label study, showing that in this study Cinryze(TM) C1 inhibitor therapy successfully treated all types of acute hereditary angioedema (HAE) attacks seen in the study through the date of analysis. Patients suffering acute attacks of HAE who were treated with Cinryze experienced improvement in symptoms at a median time of 30 minutes post treatment. None of the subjects in this study treated for laryngeal attacks required hospitalization or intubation. The findings were presented today at the American College of Allergy, Asthma and Immunology (ACAAI) 2008 Annual Meeting in Seattle, WA.

"The open label extension study findings indicated Cinryze was well tolerated in this study, and successfully treated all of the types of acute HAE attacks seen during the trial," said Bruce Zuraw, MD, professor of medicine, University of San Diego, who presented the data. "These results recognize the potential for Cinryze to treat acute attacks of HAE."

Dr. Zuraw discussed these data in a presentation entitled "Results of open-label administration of nanofiltered C1-inhibitor for the treatment of acute HAE attacks." Eighty-eight (88) subjects with documented HAE were screened and enrolled in an acute treatment open-label protocol. Subjects were eligible to receive open-label injections of Cinryze for acute attacks of angioedema occurring at any anatomical site. Subjects could receive a second open-label injection of Cinryze 60 minutes later if they had n
'/>"/>